Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients
Circulating tumor cells (CTCs) have been studied using multiple technical approaches for interrogating various cancers, as they allow for the real-time assessment of tumor progression, disease recurrence, treatment response, and tumor molecular profiling without the need for a tumor tissue biopsy. H...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/4/859 |
| _version_ | 1797482117682167808 |
|---|---|
| author | Yoshiaki Shoji Matias A. Bustos Rebecca Gross Dave S. B. Hoon |
| author_facet | Yoshiaki Shoji Matias A. Bustos Rebecca Gross Dave S. B. Hoon |
| author_sort | Yoshiaki Shoji |
| collection | DOAJ |
| description | Circulating tumor cells (CTCs) have been studied using multiple technical approaches for interrogating various cancers, as they allow for the real-time assessment of tumor progression, disease recurrence, treatment response, and tumor molecular profiling without the need for a tumor tissue biopsy. Here, we will review studies from the last 15 years on the assessment of CTCs in cutaneous melanoma patients in relation to different clinical outcomes. The focus will be on CTC detection in blood samples obtained from cutaneous melanoma patients of different clinical stages and treatments utilizing multiple platforms. Assessment of multiple molecular melanoma-associated antigen (MAA) markers by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was the most common assay allowing for the improvement of assay sensitivity, tumor heterogeneity, and to predict patient outcomes. Multicenter studies demonstrate the utility of CTC assays reducing the bias observed in single- center trials. The recent development of CTC enrichment platforms has provided reproducible methods. CTC assessment enables both multiple mRNAs and DNAs genomic aberration profiling. CTC provides specific important translational information on tumor progression, prediction of treatment response, and survival outcomes for cutaneous melanoma patients. The molecular studies on melanoma CTCs have provided and may set standards for other solid tumor CTC analyses. |
| first_indexed | 2024-03-09T22:24:44Z |
| format | Article |
| id | doaj.art-0bee92474375434c91b0496acef215e9 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:24:44Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-0bee92474375434c91b0496acef215e92023-11-23T19:07:29ZengMDPI AGCancers2072-66942022-02-0114485910.3390/cancers14040859Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma PatientsYoshiaki Shoji0Matias A. Bustos1Rebecca Gross2Dave S. B. Hoon3Department of Translational Molecular Medicine, Saint John’s Cancer Institute (SJCI), 2200 Santa Monica Blvd., Santa Monica, CA 90404, USADepartment of Translational Molecular Medicine, Saint John’s Cancer Institute (SJCI), 2200 Santa Monica Blvd., Santa Monica, CA 90404, USADepartment of Translational Molecular Medicine, Saint John’s Cancer Institute (SJCI), 2200 Santa Monica Blvd., Santa Monica, CA 90404, USADepartment of Translational Molecular Medicine, Saint John’s Cancer Institute (SJCI), 2200 Santa Monica Blvd., Santa Monica, CA 90404, USACirculating tumor cells (CTCs) have been studied using multiple technical approaches for interrogating various cancers, as they allow for the real-time assessment of tumor progression, disease recurrence, treatment response, and tumor molecular profiling without the need for a tumor tissue biopsy. Here, we will review studies from the last 15 years on the assessment of CTCs in cutaneous melanoma patients in relation to different clinical outcomes. The focus will be on CTC detection in blood samples obtained from cutaneous melanoma patients of different clinical stages and treatments utilizing multiple platforms. Assessment of multiple molecular melanoma-associated antigen (MAA) markers by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was the most common assay allowing for the improvement of assay sensitivity, tumor heterogeneity, and to predict patient outcomes. Multicenter studies demonstrate the utility of CTC assays reducing the bias observed in single- center trials. The recent development of CTC enrichment platforms has provided reproducible methods. CTC assessment enables both multiple mRNAs and DNAs genomic aberration profiling. CTC provides specific important translational information on tumor progression, prediction of treatment response, and survival outcomes for cutaneous melanoma patients. The molecular studies on melanoma CTCs have provided and may set standards for other solid tumor CTC analyses.https://www.mdpi.com/2072-6694/14/4/859biomarkerscirculating tumor cellsliquid biopsymelanomamolecular diagnostic techniques |
| spellingShingle | Yoshiaki Shoji Matias A. Bustos Rebecca Gross Dave S. B. Hoon Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients Cancers biomarkers circulating tumor cells liquid biopsy melanoma molecular diagnostic techniques |
| title | Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients |
| title_full | Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients |
| title_fullStr | Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients |
| title_full_unstemmed | Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients |
| title_short | Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients |
| title_sort | recent developments of circulating tumor cell analysis for monitoring cutaneous melanoma patients |
| topic | biomarkers circulating tumor cells liquid biopsy melanoma molecular diagnostic techniques |
| url | https://www.mdpi.com/2072-6694/14/4/859 |
| work_keys_str_mv | AT yoshiakishoji recentdevelopmentsofcirculatingtumorcellanalysisformonitoringcutaneousmelanomapatients AT matiasabustos recentdevelopmentsofcirculatingtumorcellanalysisformonitoringcutaneousmelanomapatients AT rebeccagross recentdevelopmentsofcirculatingtumorcellanalysisformonitoringcutaneousmelanomapatients AT davesbhoon recentdevelopmentsofcirculatingtumorcellanalysisformonitoringcutaneousmelanomapatients |